| Market Cap | 319.63K | P/E | - | EPS this Y | -2.60% | Ern Qtrly Grth | - |
| Income | -259.09M | Forward P/E | -0.01 | EPS next Y | 9.70% | 50D Avg Chg | -78.00% |
| Sales | 310.67M | PEG | 0.00 | EPS past 5Y | -61.91% | 200D Avg Chg | -98.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | 15.00% | 52W High Chg | -99.00% |
| Recommedations | 3.00 | Quick Ratio | 0.16 | Shares Outstanding | 10.78M | 52W Low Chg | 191.00% |
| Insider Own | 14.26% | ROA | -7.80% | Shares Float | 8.84M | Beta | 0.94 |
| Inst Own | 38.91% | ROE | - | Shares Shorted/Prior | 1.24M/1.05M | Price | 0.03 |
| Gross Margin | 18.03% | Profit Margin | -83.40% | Avg. Volume | 272,265 | Target Price | 4.00 |
| Oper. Margin | -18.21% | Earnings Date | Aug 22 | Volume | 27,369 | Change | 0.00% |
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's product portfolio includes Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, and Verapamil SR tablets, as well as Numbrino nasal solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania. On May 2, 2023, Lannett Company, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
